CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates through human trials.
A 3-D illustration of CAR-T cell therapy in breast cancer.Adobe
By Allison DeAngelis
May 14, 2026
Biotech Startups and Venture Capital Reporter
Allison DeAngelis
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
The world’s first CAR-T therapy for solid tumors has passed muster in China, with the country's National Medical Products…
Waypoint Bio Raises $20M Series A Led by Amplify Partners to Advance AI-Designed Cell Therapies Toward the Clinic
Legend Biotech’s long-awaited first showing of in vivo CAR-T data is here, fueling momentum in the growing field.
The emerging cancer treatment that’s exciting scientists: ‘We’ve just scratched the surface on what’s possible’
